Watch CYT-6091 in Action

We injected CYT-6091, CytImmune’s 1st generation nanomedicine, into a mouse with a tumor. We also injected a protein called albumin, to which a florescent dye was attached. This allowed us to track the albumin as it moved through blood vessels of the mouse. The albumin remains inside healthy tissue blood vessels, but easily passes through…

Attacking Metastatic Breast Cancer

CytImmune wants to help individuals living with metastatic breast cancer live longer and maintain a high quality of life. We hope you will support our efforts to advance our technology through a Phase II clinical trial.

Shooting for 95%

We have created a nanotechnology based cancer therapy that we believe is capable of delivering a 95% response rate to solid tumor cancer patients. Why are we so confident? Because it’s already been done. SOME BACKGROUND A characteristic of the micro-environment in all solid tumors, and a primary driver of cancer therapy failures, is high…